Loading...

Expanding International Healthcare Access And Efficiencies Will Unlock Value

Published
11 May 25
Updated
16 Aug 25
AnalystConsensusTarget's Fair Value
US$8.00
92.9% undervalued intrinsic discount
28 Aug
US$0.57
Loading
1Y
-81.9%
7D
-8.6%

Author's Valuation

US$8.0

92.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on16 Aug 25
Fair value Decreased 7.69%

The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.